Skip to main content

Table 5 Resistance proportion of priority bacteria-antimicrobial combinations in all specimens and in blood and CSF, in 2012 and 2016. Denominators and numerators are the numbers of tested and resistant isolates respectively. Corresponding resistant percentages are in brackets

From: Antimicrobial susceptibility testing results from 13 hospitals in Viet Nam: VINARES 2016–2017

 

Bacteria

All specimens

Blood and CSF (stool for Salmonella spp. and Shigella spp.)

2012 (16 hospitals)

2012 (13 hospitals)

2016

2012 (16 hospitals)

2012 (13 hospitals)

2016

ESBL

E. coli

1337/1928 (69%)

626/844 (74%)

4085/6953 (59%)

126/183 (69%)

59/81 (73%)

655/1107 (59%)

Imipenem

E. coli

180/2 977 (6%)

145/2111 (7%)

687/8438 (8%)

15/403 (4%)

9/309 (3%)

92/1410 (7%)

Ceftriaxone

E. coli

2342/4 192 (56%)

776/1472 (53%)

5051/7049 (72%)

240/514 (47%)

114/234 (49%)

912/1324 (69%)

MDR

E. coli

453/1828 (25%)

441/1639 (27%)

2015/6956 (29%)

24/125 (19%)

24/125 (19%)

336/1204 (28%)

XDR

E. coli

71/1828 (4%)

63/1639 (4%)

514/6956 (7%)

2/125 (2%)

2/125 (2%)

65/1204 (5%)

ESBL

K. pneumoniae

887/1400 (63%)

555/815 (68%)

1186/2958 (40%)

91/172 (53%)

34/61 (56%)

128/365 (35%)

Imipenem

K. pneumoniae

393/2 294 (17%)

259/1697 (15%)

891/3647 (24%)

64/361 (18%)

26/233 (11%)

91/454 (20%)

Ceftriaxone

K. pneumoniae

1479/2 227 (66%)

626/1380 (45%)

1912/3436 (56%)

101/190 (53%)

63/175 (36%)

214/435 (49%)

MDR

K. pneumoniae

318/1553 (20%)

294/1315 (22%)

428/3141 (14%)

17/112 (15%)

17/112 (15%)

53/403 (13%)

XDR

K. pneumoniae

205/1553 (13%)

171/1315 (13%)

722/3141 (23%)

12/112 (11%)

12/112 (11%)

81/403 (20%)

Imipenem

A. baumannii

1495/2138 (70%)

1056/1584 (67%)

2769/3551 (78%)

110/244 (45%)

85/205 (41%)

100/178 (56%)

MDR

A. baumannii

897/1334 (67%)

897/1282 (70%)

2781/3442 (81%)

27/44 (61%)

27/44 (61%)

101/171 (59%)

Imipenem

P. aeruginosa

578/1 765 (33%)

322/996 (32%)

1403/3220 (44%)

36/129 (28%)

22/88 (25%)

49/135 (36%)

MDR

P. aeruginosa

178/576 (31%)

144/392 (37%)

660/1566 (42%)

4/25 (16%)

4/17 (24%)

17/70 (24%)

MRSA

S. aureus

1 098/1 580 (69%)

950/1303 (73%)

3302/4515 (73%)

145/197 (74%)

130/171 (76%)

476/674 (71%)

Vancomycin*

S. aureus

28/823 (3.4%)

10/372 (2%)

45/2680 (2%)

5/135 (3.7%)

0/65 (0%)

7/565 (1%)

Penicillin

S. pneumoniae

115/344 (33%)**

115/341 (34%)**

663/1136(58%)

7/30 (23%) **

7/30 (23%) **

42/114 (37%)

Ceftriaxone

S. pneumoniae

90/358 (25%)

31/299 (10.4%)

57/352 (16%)

9/52 (17%)

4/47 (8.5%)

17/125 (14%)

Vancomycin

E. faecium

20/79 (25%)

20/79 (25%)

91/290 (31%)

2/14 (14%)

2/14 (14%)

13/51 (25%)

Ampicillin

H. influenzae

160/226 (71%)

1/1 (100%)

804/911 (88%)

3/5 (60%)

1/1 (100%)

7/8 (88%)

  1. ESBL: extended-spectrum β-lactamase; *: Intermediate and Resistant; **: Combination result of oxacillin screening and penicillin MIC test; MDR: Multi-drug resistant; XDR: Extensively drug resistant; MRSA: Methicillin-resistant Staphylococcus aureus